Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263957 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL20691935 | 0.84 | P2RX3 (0.42) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL20691298 | 0.83 | AHCY (0.37) | TYMP | |
| SCHEMBL22349203 | 0.79 | STING1 (0.38) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL8537379 | 0.78 | ALDH1A1 (0.56) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL8338176 | 0.78 | ALDH1A1 (0.56) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL20692221 | 0.75 | P2RX3 (0.36) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL20691336 | 0.75 | RNASEL (0.42) | ALDH1A1P2RX3 | |
| SCHEMBL9310418 | 0.71 | ALDH1A1 (0.58) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL9309087 | 0.71 | ALDH1A1 (0.58) | ALDH1A1LMNAALBMAPK1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | ALDH1A1 1444/4885LMNA 1855/4885ALB 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.